

Head and Neck Cancer Pathways

Patient Name: _____ Date of Birth: _____

Member ID: _____ Treatment Start Date: _____

Stage: _____ Pathology: _____

ECOG Status: 1 2 3 4 ICD-10 Code: _____

Line of Therapy:

Neoadjuvant /Pre-op Adjuvant /Post Op 1st Line 2nd Line

Biomarkers/Attributes: (select all that apply)

PD-L1:	<input type="checkbox"/> 1 - 49%	<input type="checkbox"/> ≥ 50%	<input type="checkbox"/> Negative	<input type="checkbox"/> ≥ CPS 1	<input type="checkbox"/> ≥ CPS 20	<input type="checkbox"/> Not Reported
Prior Immunotherapy given:	<input type="checkbox"/> Yes	<input type="checkbox"/> No	<input type="checkbox"/> Not Reported			

Primary Definitive Therapy

Non-nasopharyngeal

Cisplatin + concurrent radiation therapy

Nasopharyngeal

Cisplatin + concurrent radiation therapy
 Cisplatin + Gemcitabine

Adjuvant Therapy

Non-nasopharyngeal

Cisplatin + concurrent radiation therapy

Nasopharyngeal

Cisplatin + Fluorouracil (5FU)
 Carboplatin + Fluorouracil (5FU)

Recurrent/Metastatic/Unresectable

Non-nasopharyngeal | First line of therapy

Cisplatin or Carboplatin + Fluorouracil (5FU) + Cetuximab
 Cisplatin + Fluorouracil (5FU)
 Cisplatin or Carboplatin + Docetaxel
 Cisplatin or Carboplatin + Paclitaxel
 Cisplatin or Carboplatin + Fluorouracil (5FU) + Pembrolizumab
 Pembrolizumab (PD-L1 expression with CPS ≥ 1)

Non-nasopharyngeal | Maintenance

Cetuximab
 Pembrolizumab (PD-L1 expression with CPS ≥ 1)

Non-nasopharyngeal | Second and Subsequent Lines of Therapy

Nivolumab (if IO not previously used)

Note: Pathways are independent of specific OptumCare/health plan medical policy coverage criteria. OptumCare/health plan medical policy/clinical guidelines should be consulted to determine whether proposed services will be covered. Biosimilars or alternate formulations (along with the reference products) are considered on pathway unless otherwise specified by OptumCare/health plan formularies, medical policies, or preferred product rules.

- Pembrolizumab (if IO not previously used)
- Cisplatin or Carboplatin + Fluorouracil (5FU) + Cetuximab
- Cisplatin + Fluorouracil (5FU)
- Cisplatin or Carboplatin + Docetaxel
- Cisplatin or Carboplatin + Paclitaxel

Nasopharyngeal | First Line of Therapy

- Cisplatin + Gemcitabine

References:

Adelstein, D.J., Li, Y., Adams, G.L., et al. An Intergroup Phase III Comparison of Standard Radiation Therapy and Two Schedules of Concurrent Chemoradiotherapy in Patients With Unresectable Squamous Cell Head and Neck Cancer. *J Clin Oncol.* 2003;21(1):92-98. doi:10.1200/JCO.2003.01.008

Al-Sarraf, M., LeBlanc, M, Giri, P.G., et al. Chemoradiotherapy Versus Radiotherapy in Patients With Advanced Nasopharyngeal Cancer: Phase III Randomized Intergroup Study 0099. *J Clin Oncol.* 1998; 16: 1310-1317

Al-Sarraf, M., Metch, B., Kish, J., et al. Platinum Analogs in Recurrent and Advanced Head and Neck Cancer: A Southwest Oncology Group and Wayne State University Study. *Cancer Treat Rep.* 1987;71(7-8):723-726

Bachaud, J.M., Cohen-Jonathan, E., Alzieu, C., et al. Combined Postoperative Radiotherapy and Weekly Cisplatin Infusion for Locally Advanced Head and Neck Carcinoma: Final Report of a Randomized Trial. *Int J Radiat Oncol Biol Phys.* 1996;36(5):999-1004. doi:10.1016/s0360-3016(96)00430-0

Bae, W.K., Hwang, J.E., Shim, H.J., et al. Phase II Study of Docetaxel, Cisplatin and 5-FU Induction Chemotherapy Followed by Chemoradiotherapy in Locoregionally Advanced Nasopharyngeal Cancer. *Cancer Chemother Pharmacol.* 2010; 65: 589-595

Bernier, J., Domenge, C., Ozsahin, M., et al. Postoperative Irradiation With or Without Concomitant Chemotherapy for Locally Advanced Head and Neck Cancer. *N Engl J Med.* 2004;350(19):1945-1952. doi:10.1056/NEJMoa032641

Blanchard, P., Lee, A., Marguet, S., et al. Chemotherapy and Radiotherapy in Nasopharyngeal Carcinoma: An Update of the MAC-NPC Meta-Analysis. *Lancet Oncol.* 2015; 16: 645-655

Bonner, J.A., Harari, P.M., Giralt, J., et al. Radiotherapy Plus Cetuximab for Squamous-Cell Carcinoma of the Head and Neck. *N Engl J Med.* 2006;354(6):567-578. doi:10.1056/NEJMoa053422

Bossi, P., Miceli, R., Locati, L.D., et al. A Randomized, Phase 2 Study of Cetuximab Plus Cisplatin With or Without Paclitaxel for the First-Line Treatment of Patients With Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck. *Ann Oncol.* 2017;28(11):2820-2826. doi:10.1093/annonc/mdx439

Bourhis, J., Sire, C., Graff, P., et al. Concomitant Chemoradiotherapy Versus Acceleration of Radiotherapy With or Without Concomitant Chemotherapy in Locally Advanced Head and Neck Carcinoma (GORTEC 99-02): An Open-Label Phase 3 Trial. *Lancet Oncol.* 2012;13(2):145-153. doi:10.1016/S1470-2045(11)70346-1

Note: Pathways are independent of specific OptumCare/health plan medical policy coverage criteria. OptumCare/health plan medical policy/clinical guidelines should be consulted to determine whether proposed services will be covered. Biosimilars or alternate formulations (along with the reference products) are considered on pathway unless otherwise specified by OptumCare/health plan formularies, medical policies, or preferred product rules.

Burtness, B., Goldwasser, M.A., Flood, W., et al. Phase III Randomized Trial of Cisplatin Plus Placebo Compared With Cisplatin Plus Cetuximab in Metastatic/Recurrent Head and Neck Cancer: An Eastern Cooperative Oncology Group Study. *J Clin Oncol.* 2005;23:8646-8654

Burtness, B., Goldwasser, M.A., Flood, W., et al., Eastern Cooperative Oncology Group. Phase III Randomized Trial of Cisplatin Plus Placebo Compared With Cisplatin Plus Cetuximab in Metastatic/Recurrent Head and Neck Cancer: An Eastern Cooperative Oncology Group Study [published correction appears in *J Clin Oncol.* 2006 Feb 1;24(4):724]. *J Clin Oncol.* 2005;23(34):8646-8654. doi:10.1200/JCO.2005.02.4646

Burtness, B., Harrington, K.J., Greil, R., et al. Pembrolizumab Alone or With Chemotherapy Versus Cetuximab With Chemotherapy for Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (KEYNOTE-048): An Open-Label, Phase 3 Study [published correction appears in *Lancet.* 2020 Jan 25;395(10220):272] [published correction appears in *Lancet.* 2020 Feb 22;395(10224):564]. *Lancet.* 2019;394(10212):1915-1928. doi:10.1016/S0140-6736(19)32591-7

Catimel, G., Verweij, J., Mattijssen, V., et al. Docetaxel (Taxotere®): An Active Drug for the Treatment of Patients With Advanced Squamous Cell Carcinoma of the Head and Neck. EORTC Early Clinical Trial Group. *AnnOncol* 1994; 5:533–537

Chan, A.T., Leung, S.F., Ngan, R.K., et al. Overall Survival After Concurrent Cisplatin-Radiotherapy Compared With Radiotherapy Alone in Locoregionally Advanced Nasopharyngeal Carcinoma. *J Natl Cancer Inst.* 2005; 97:536-539

Chan, A.T.C., Hsu, M.-M., Goh, B.C., et al. Multicenter, Phase II Study of Cetuximab in Combination With Carboplatin in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma. *J Clin Oncol.* 2005;23:3568-3576

Chen, L., Hu, C.S., Chen, X.Z., et al. Concurrent Chemoradiotherapy Plus Adjuvant Chemotherapy Versus Concurrent Chemoradiotherapy Alone in Patients With Locoregionally Advanced Nasopharyngeal Carcinoma: A Phase 3 Multicentre Randomized Controlled Trial. *Lancet Oncol.* 2012; 13:163-171

Chen, Y.P., Tang, L.L., Yang, Q., et al. Induction Chemotherapy Plus Concurrent Chemoradiotherapy in Endemic Nasopharyngeal Carcinoma: Individual Patient Data Pooled Analysis of Four Randomized Trials. *Clin Cancer Res.* 2018; 24:1824-1833

Chitapanarux, I., Lorvidhaya, V., Kamnerdsupaphon, P., et al. Chemoradiation Comparing Cisplatin Versus Carboplatin in Locally Advanced Nasopharyngeal Cancer: Non-Inferiority, Open Trial. *Eur J Cancer.* 2007;43(9):1399-1406. doi:10.1016/j.ejca.2007.03.022

Cohen, E.E.W., Soulières, D., Le Tourneau, C., et al. Pembrolizumab Versus Methotrexate, Docetaxel, or Cetuximab for Recurrent or Metastatic Head-and-Neck Squamous Cell Carcinoma (KEYNOTE-040): A Randomized, Open-Label, Phase 3 Study [published correction appears in *Lancet.* 2019 Jan 12;393(10167):132]. *Lancet.* 2019;393(10167):156-167. doi:10.1016/S0140-6736(18)31999-8

Cooper, J.S., Pajak, T.F., Forastiere, A.A., et al. Postoperative Concurrent Radiotherapy and Chemotherapy for High-Risk Squamous-Cell Carcinoma of the Head and Neck. *N Engl J Med.* 2004;350(19):1937-1944. doi:10.1056/NEJMoa032646

Cooper, J.S., Zhang, Q., Pajak, T.F., et al. Long-Term Follow-Up of the RTOG 9501/Intergroup Phase III Trial: Postoperative Concurrent Radiation Therapy and Chemotherapy in High-Risk Squamous Cell Carcinoma of the Head and Neck. *Int J Radiat Oncol Biol Phys.* 2012;84(5):1198-1205. doi:10.1016/j.ijrobp.2012.05.008

Note: Pathways are independent of specific OptumCare/health plan medical policy coverage criteria. OptumCare/health plan medical policy/clinical guidelines should be consulted to determine whether proposed services will be covered. Biosimilars or alternate formulations (along with the reference products) are considered on pathway unless otherwise specified by OptumCare/health plan formularies, medical policies, or preferred product rules.

Dechaphunkul T., Pruegsanusak, K., Sangthawan, D., et al. Concurrent Chemoradiotherapy With Carboplatin Followed by Carboplatin and 5-Fluorouracil in Locally Advanced Nasopharyngeal Carcinoma. *Head Neck Oncol.* 2011; 3:30

Delord, J.P., Hollebecque, A., de Boer, J.P., et al. An Open-Label, Multicohort, Phase I/II Study to Evaluate Nivolumab in Patients With Virus-Associated Tumors (Checkmate 358): Efficacy and Safety in Recurrent or Metastatic (R/M) Nasopharyngeal Carcinoma (NPC). *J Clin Oncol.* 2017;35(suppl 15): Abstract 6025

Denis, F., Garaud, P., Bardet, E., et al. Final results of the 94-01 French Head and Neck Oncology and Radiotherapy Group Randomized Trial Comparing Radiotherapy Alone With Concomitant Radiochemotherapy in Advanced-Stage Oropharynx Carcinoma. *J Clin Oncol.* 2004;22(1):69-76. doi:10.1200/JCO.2004.08.021

Ferris, R.L., Blumenschein, Jr., G., Fayette, J., et al. Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck. *N Engl J Med.* 2016;375(19):1856-1867. doi:10.1056/NEJMoa1602252

Ferris, R.L., Blumenschein, Jr., G., Fayette, J., et al. Nivolumab vs. Investigator's Choice in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck: 2-Year Long-Term Survival Update of Checkmate 141 With Analyses by Tumor PD-L1 Expression. *Oral Oncol.* 2018;81:45-51. doi:10.1016/j.oraloncology.2018.04.008

Forastiere, A.A., Goepfert, H., Maor, M., et al. Concurrent Chemotherapy and Radiotherapy for Organ Preservation in Advanced Laryngeal Cancer. *N Engl J Med* 349:2091-2098, 2003

Forastiere, A.A., Metch, B., Schuller, D.E., et al. Randomized Comparison of Cisplatin Plus Fluorouracil and Carboplatin Plus Fluorouracil Versus Methotrexate in Advanced Squamous-Cell Carcinoma of the Head and Neck: A Southwest Oncology Group Study. *J Clin Oncol.* 1992;10(8):1245-1251. doi:10.1200/JCO.1992.10.8.1245

Forastiere, A.A., Zhang, Q., Weber, R.S., et al. Long-Term Results of RTOG 91-11: A Comparison of Three Nonsurgical Treatment Strategies to Preserve the Larynx in Patients With Locally Advanced Larynx Cancer. *J Clin Oncol.* 2013;31(7):845-852. doi:10.1200/JCO.2012.43.6097

Fountzilas, G., Tolis, C., Kalogera-Fountzila, A., et al. Induction Chemotherapy With Cisplatin, Epirubicin and Paclitaxel (CEP), Followed by Concomitant Radiotherapy and Weekly Paclitaxel for the Management of Locally Advanced Nasopharyngeal Carcinoma. A Hellenic Cooperative Oncology Group Phase II Study. *Strahlenther Onkol.* 2005; 181(4): 223-30

Garden, A.S., Harris, J., Vokes, E.E., et al. Preliminary Results of Radiation Therapy Oncology Group 97-03: A Randomized Phase II Trial of Concurrent Radiation and Chemotherapy for Advanced Squamous Cell Carcinomas of the Head and Neck. *J Clin Oncol.* 2004;22(14):2856-2864. doi:10.1200/JCO.2004.12.012

Gibson, M.K., Li, Y., Murphy, B., et al. Randomized Phase III Evaluation of Cisplatin Plus Fluorouracil Versus Cisplatin Plus Paclitaxel in Advanced Head and Neck Cancer (E1395): An Intergroup Trial of the Eastern Cooperative Oncology Group. *J Clin Oncol.* 2005;23(15):3562-3567. doi:10.1200/JCO.2005.01.057

Gibson, M.K., Li, Y., Murphy, B., et al. Randomized Phase III Evaluation of Cisplatin Plus Fluorouracil Versus Cisplatin Plus Paclitaxel in Advanced Head and Neck Cancer (E1395): An Intergroup Trial of the Eastern Cooperative Oncology Group. *J Clin Oncol.* 2005;23:3562-3567

Note: Pathways are independent of specific OptumCare/health plan medical policy coverage criteria. OptumCare/health plan medical policy/clinical guidelines should be consulted to determine whether proposed services will be covered. Biosimilars or alternate formulations (along with the reference products) are considered on pathway unless otherwise specified by OptumCare/health plan formularies, medical policies, or preferred product rules.

Gillison, M.L., Trotti, A.M., Harris, J., et al. Radiotherapy Plus Cetuximab or Cisplatin in Human Papillomavirus-Positive Oropharyngeal Cancer (NRG Oncology RTOG 1016): A Multicentre, NonInferiority Trial [published correction appears in *Lancet*. 2020 Mar 7;395(10226):784]. *Lancet*. 2019;393(10166):40-50. doi:10.1016/S0140-6736(18)32779-X

Grau, J.J., Caballero, M., Verger, E., et al. Weekly Paclitaxel for Platin-Resistant Stage IV Head and Neck Cancer Patients. *Acta Otolaryngol*. 2009;129(11):1294-1299. doi:10.3109/00016480802590451

Guardiola, E., Peyrade, F., Chaigneau, L., et al. Results of a Phase II Study Comparing Docetaxel With Methotrexate in Patients With Recurrent Head and Neck Cancer. *Eur J Cancer*. 2004;40(14):2071-2076. doi:10.1016/j.ejca.2004.05.019

Guigay, J., Fayette, J., Dillies, A.F., et al. Cetuximab, Docetaxel and Cisplatin as First-Line Treatment in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: A Multicenter, Phase II GORTEC Study. *Ann Oncol*. 2015;26(9):1941-1947. doi:10.1093/annonc/mdv268

Guigay, J., Fayette, J., Mesia, R., et al. TPEXtreme Randomized Trial: TPEX Versus Extreme Regimen in 1st Line Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC). *J Clin Oncol*. 37, 2019 (suppl; abstr 6002). doi: 10.1200/JCO.2019.37.15_suppl.6002

Haddad, R., O'Neill, A., Rabinowits, G., et al. Induction Chemotherapy Followed by Concurrent Chemoradiotherapy (Sequential Chemoradiotherapy) Versus Concurrent Chemoradiotherapy Alone in Locally Advanced Head and Neck Cancer (PARADIGM): A Phase 3 Trial. *Lancet Oncol*. 2013;14(3):257-264. doi:10.1016/S1470-2045(13)70011-1

Hanemaaijer, S.H., Kok, I.C., Fehrmann, R.S.N., et al. Comparison of Carboplatin With 5-Fluorouracil vs. Cisplatin as Concomitant Chemoradiotherapy for Locally Advanced Head and Neck Squamous Cell Carcinoma. *Front Oncol*. 2020;10:761. Published 2020 Jun 5. doi:10.3389/fonc.2020.00761

Harari, P.M., Harris, J., Kies, M.S., et al. Postoperative Chemoradiotherapy and Cetuximab for High-Risk Squamous Cell Carcinoma of the Head and Neck: Radiation Therapy Oncology Group RTOG-0234. *J Clin Oncol*. 2014;32(23):2486-2495. doi:10.1200/JCO.2013.53.9163

Hitt, R., López-Pousa, A., Martínez-Trufero, J., et al. Phase III Study Comparing Cisplatin Plus Fluorouracil to Paclitaxel, Cisplatin and Fluorouracil Induction Chemotherapy Followed by Chemoradiotherapy in Locally Advanced Head and Neck Cancer [published correction appears in *J Clin Oncol*. 2006 Feb. 20;24(6):1015]. *J Clin Oncol*. 2005;23(34):8636-8645. doi:10.1200/JCO.2004.00.1990

Hsu, C., Lee, S.H., Ejadi, S., et al. Safety and Antitumor Activity of Pembrolizumab in Patients With Programmed Death-Ligand 1-Positive Nasopharyngeal Carcinoma: Results of the KEYNOTE-028 Study. *J Clin Oncol*. 2017;35:4050-4056

Hui, E.P., Ma, B.B., Leung, S.F., et al. Randomized Phase II Trial of Concurrent Cisplatin-Radiotherapy With or Without Neoadjuvant Docetaxel and Cisplatin in Advanced Nasopharyngeal Carcinoma. *J Clin Oncol*. 2009; 27: 242-249

Jacobs, C., Lyman, G., Velez-Garcia, E., et al. A Phase III Randomized Study Comparing Cisplatin and Fluorouracil as Single Agents and in Combination for Advanced Squamous Cell Carcinoma of the Head and Neck. *J Clin Oncol*. 1992;10:257-263

Jacobs, C., Lyman, G., Velez-García, E., et al. A Phase III Randomized Study Comparing Cisplatin and Fluorouracil as Single Agents and in Combination for Advanced Squamous Cell Carcinoma of the Head and Neck. *J Clin Oncol*. 1992;10(2):257-263. doi:10.1200/JCO.1992.10.2.257

Note: Pathways are independent of specific OptumCare/health plan medical policy coverage criteria. OptumCare/health plan medical policy/clinical guidelines should be consulted to determine whether proposed services will be covered. Biosimilars or alternate formulations (along with the reference products) are considered on pathway unless otherwise specified by OptumCare/health plan formularies, medical policies, or preferred product rules.

Janoray, G., Pointreau, Y., Garaud, P., et al. Long-Term Results of a Multicenter Randomized Phase III Trial of Induction Chemotherapy With Cisplatin, 5-fluorouracil, ± Docetaxel for Larynx Preservation. *J Natl Cancer Inst.* 2015;108(4):djv368. Published 2015 Dec 16. doi:10.1093/jnci/djv368

Jin, Y., Cai, X.Y., Shi, Y.X., et al. Comparison of Five Cisplatin-Based Regimens Frequently Used as the First-Line Protocols in Metastatic Nasopharyngeal Carcinoma. *J Cancer Res Clin Oncol.* 2012;138:1717- 1725

Lee, A.W., Tung, S.Y., Ng, W.T., et al. A Multicenter, Phase 3, Randomized Trial of Concurrent Chemoradiotherapy Plus Adjuvant Chemotherapy Versus Radiotherapy Alone in Patients With Regionally Advanced Nasopharyngeal Carcinoma: 10-Year Outcomes for Efficacy and Toxicity. *Cancer.* 2017; 123(21):4147-4157

Lefebvre, J.L., Pointreau, Y., Rolland, F., et al. Induction Chemotherapy Followed by Either Chemoradiotherapy or Bioradiotherapy for Larynx Preservation: The TREMPLIN Randomized Phase II Study [Published Correction Appears in *J Clin Oncol.* 2013 May 1;31(13):1702]. *J Clin Oncol.* 2013;31(7):853-859. doi:10.1200/JCO.2012.42.3988

Leong, S.S., Wee, J., Tay, M.H., et al. Paclitaxel, Carboplatin and Gemcitabine in Metastatic Nasopharyngeal Carcinoma: A Phase II Trial Using a Triplet Combination. *Cancer* 2005;103:569-575

Ma, B.B.Y., Lim, W.T., Goh, B.C., et al. Antitumor Activity of Nivolumab in Recurrent and Metastatic Nasopharyngeal Carcinoma: An International, Multicenter Study of the Mayo Clinic Phase 2 Consortium (NCI-9742). *J Clin Oncol.* 2018;36:1412-1418

Machiels, J.P., Haddad, R.I., Fayette, J., et al. Afatinib Versus Methotrexate as Second-Line Treatment in Patients With Recurrent or Metastatic Squamous-Cell Carcinoma of the Head and Neck Progressing On or After Platinum-Based Therapy (LUX-Head & Neck 1): An Open-Label, Phase 3 Trial. *Lancet Oncol.* 2015;16(5):583-594. doi:10.1016/S1470-2045(15)70124-5

Marabelle A, Le DT, Ascierto PA, et al. Efficacy of pembrolizumab in patients with noncolorectal high microsatellite instability/mismatch repair-deficient cancer: results from the phase II KEYNOTE-158 study. *J Clin Oncol* 2020;38: 1-10.

Martinez-Trufero, J., Isla D., Adansa, J.C., et al. Phase II Study of Capecitabine as Palliative Treatment for Patients With Recurrent and Metastatic Squamous Head and Neck Cancer After Previous Platinum Based Treatment. *Br J Cancer.* 2010;102(12):1687-1691. doi:10.1038/sj.bjc.6605697

Medina, J.A., Rueda, A., de Pasos, A.S., et al. A Phase II Study of Concomitant Boost Radiation Plus Concurrent Weekly Cisplatin for Locally Advanced Unresectable Head and Neck Carcinomas. *Radiother Oncol.* 2006;79(1):34-38. doi:10.1016/j.radonc.2006.03.010

National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology. Accessed Aug. 20, 2020

Noronha, V., Joshi, A., Patil, V.M., et al. Once-a-Week Versus Once-Every-3-Weeks Cisplatin Chemoradiation for Locally Advanced Head and Neck Cancer: A Phase III Randomized Noninferiority Trial. *J Clin Oncol.* 2018;36(11):1064-1072. doi:10.1200/JCO.2017.74.9457

Pignon, J.P., le Maître, A., Maillard, E., Bourhis, J., MACH-NC Collaborative Group. Meta-Analysis of Chemotherapy in Head and Neck Cancer (MACH-NC): An Update on 93 Trials and 17,346 Patients. *Radiother Oncol.* 2009;92(1):4-14. doi:10.1016/j.radonc.2009.04.014

Note: Pathways are independent of specific OptumCare/health plan medical policy coverage criteria. OptumCare/health plan medical policy/clinical guidelines should be consulted to determine whether proposed services will be covered. Biosimilars or alternate formulations (along with the reference products) are considered on pathway unless otherwise specified by OptumCare/health plan formularies, medical policies, or preferred product rules.

Pointreau, Y., Garaud, P., Chapet, S., et al. Randomized Trial of Induction Chemotherapy With Cisplatin And 5-Fluorouracil With or Without Docetaxel for Larynx Preservation. *J Natl Cancer Inst.* 2009;101(7):498-506. doi:10.1093/jnci/djp007

Posner, M.R., Hershock, D.M., Blajman, C.R., et al. Cisplatin and Fluorouracil Alone or With Docetaxel in Head and Neck Cancer. *N Engl J Med.* 2007;357(17):1705-1715. doi:10.1056/NEJMoa070956

Ribassin-Majed, L., Marguet, S., Lee, A., et al. What Is the Best Treatment of Locally Advanced Nasopharyngeal Carcinoma? An Individual Patient Data Network Meta-Analysis. *J Clin Oncol.* 2017; 35(5): 498-505

Samlowski, W.E., Moon, J., Kuebler, J.P., et al. Evaluation of the Combination of Docetaxel/Carboplatin in Patients With Metastatic or Recurrent Squamous Cell Carcinoma of the Head and Neck (SCCHN): A Southwest Oncology Group Phase II Study. *Cancer Invest.* 2007;25(3):182-188. doi:10.1080/07357900701209061

Samlowski, W.E., Moon, J., Kuebler, J.P., et al. Evaluation of the Combination Of Docetaxel/Carboplatin in Patients With Metastatic or Recurrent Squamous Cell Carcinoma of the Head and Neck (SCCHN): A Southwest Oncology Group Phase II Study. *Cancer Invest* 2007;25:182-188

Stewart, J.S., Cohen, E.E., Licitra, L., et al. Phase III Study of Gefitinib Compared With Intravenous Methotrexate for Recurrent Squamous Cell Carcinoma of the Head and Neck [corrected] [published correction appears in *J Clin Oncol.* 2009 Jul 10;27(20):3410]. *J Clin Oncol.* 2009;27(11):1864-1871. doi:10.1200/JCO.2008.17.0530

Sun, Y., Li, W.F., Chen, N.Y., et al. Induction Chemotherapy Plus Concurrent Chemoradiotherapy Versus Concurrent Chemoradiotherapy Alone in Locoregionally Advanced Nasopharyngeal Carcinoma: A Phase 3, Multicenter, Randomized Controlled Trial. *Lancet Oncol.* 2016; 17:1509-1520

Suntharalingam, M., Haas, M.L., Conley, B.A., et al. The Use of Carboplatin and Paclitaxel With Daily Radiotherapy in Patients With Locally Advanced Squamous Cell Carcinomas of the Head and Neck. *Int J Radiat Oncol Biol Phys.* 2000;47(1):49-56. doi:10.1016/s0360-3016(00)00408-9

Taylor, S.G., Murthy, A.K., Vannetzel, J.M., et al. Randomized Comparison of Neoadjuvant Cisplatin and Fluorouracil Infusion Followed by Radiation Versus Concomitant Treatment in Advanced Head and Neck Cancer. *J Clin Oncol.* 1994;12(2):385-395. doi:10.1200/JCO.1994.12.2.385

Vermorken, J.B., Mesia, R., Rivera, F., et al. Platinum-Based Chemotherapy Plus Cetuximab in Head and Neck Cancer. *N Engl J Med.* 2008;359(11):1116-1127. doi:10.1056/NEJMoa0802656

Vermorken, J.B., Remenar, E., van Herpen, C., et al. Cisplatin, Fluorouracil and Docetaxel in Unresectable Head and Neck Cancer. *N Engl J Med.* 2007;357(17):1695-1704. doi:10.1056/NEJMoa071028

Vermorken, J.B., Stöhlmacher-Williams, J., Davidenko, I., et al. Cisplatin and Fluorouracil With or Without Panitumumab in Patients With Recurrent or Metastatic Squamous-Cell Carcinoma of the Head and Neck (SPECTRUM): An Open-Label Phase 3 Trial. *Lancet Oncol.* 2013;14(8):697-710. doi:10.1016/S1470-2045(13)70181-5

Vermorken, J.B., Trigo, J., Hitt, R., et al. Open-Label, Uncontrolled, Multicenter Phase II Study to Evaluate the Efficacy and Toxicity of Cetuximab as a Single Agent in Patients With Recurrent and/or Metastatic Squamous Cell Carcinoma of

Note: Pathways are independent of specific OptumCare/health plan medical policy coverage criteria. OptumCare/health plan medical policy/clinical guidelines should be consulted to determine whether proposed services will be covered. Biosimilars or alternate formulations (along with the reference products) are considered on pathway unless otherwise specified by OptumCare/health plan formularies, medical policies, or preferred product rules.

the Head and Neck Who Failed to Respond to Platinum-Based Therapy. *J Clin Oncol.* 2007;25(16):2171-2177.
doi:10.1200/JCO.2006.06.7447

Zhang, L., Huang, Y., Hong, S., et al. Gemcitabine Plus Cisplatin Versus Fluorouracil Plus Cisplatin in Recurrent or Metastatic Nasopharyngeal Carcinoma: A Multicentre, Open-Label, Phase 3 Trial. *Lancet.* 2016;388:1883-1892

Zhang, L., Zhang, Y., Huang, P.-Y., et al. Phase II Clinical Study of Gemcitabine in the Treatment of Patients With Advanced Nasopharyngeal Carcinoma After the Failure of Platinum-Based Chemotherapy. *Cancer Chemother Pharmacol* 2008;61:33-38

Zhang, Y., Chen, L., Hu, G.Q., et al. Gemcitabine and Cisplatin Induction Chemotherapy in Nasopharyngeal Carcinoma. *N Engl J Med.* 2019; 381:1124-1135

Note: Pathways are independent of specific OptumCare/health plan medical policy coverage criteria. OptumCare/health plan medical policy/clinical guidelines should be consulted to determine whether proposed services will be covered. Biosimilars or alternate formulations (along with the reference products) are considered on pathway unless otherwise specified by OptumCare/health plan formularies, medical policies, or preferred product rules.

Last Review [2.18.2022] | Effective [3.1.2022]